AMRX
Amneal Pharmaceuticals, Inc.
AMRX has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over AMRX overall, supported by stronger fundamentals and stronger modeled upside.
AMRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Under pressure | |
| Unavailable |
AMRX's revenue and profitability are currently healthy, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $5.39 | -75% |
| Forward | 19x | $21.70 | — |
| Current | 53x | $21.70 | — |
| Fair | 58x | $23.71 | +9.2% |
| Expensive | 616x | $253 | +1064% |
Historical ranges are pointers, not guarantees.
AMRX's PE is in its fair range at 53x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AMRX in the historical PE scenario, which offers more potential upside but is not a forecast.
AMRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AMRX, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AMRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.14 | +178% |
| Q3 2026 | $0.41 | +1950% |
| Q2 2026 | $0.48 | +4700% |
| Q1 2026 | $0.37 | +$0.41 |
| Q4 2025 | $0.22 | +$0.60 |
| Q3 2025 | $0.02 | +$0.87 |
| Q2 2025 | $0.01 | +$0.80 |
| Q1 2025 | -$0.04 | +$0.69 |
| Q4 2024 | -$0.38 | +$0.10 |
AMRX has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AMRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $862.7M | +10% |
| Q2 2026 | $796.2M | +9.9% |
| Q1 2026 | $722.5M | +3.9% |
| Q4 2025 | $814.3M | +11% |
| Q3 2025 | $784.5M | +12% |
| Q2 2025 | $724.5M | +3.2% |
| Q1 2025 | $695.4M | +5.5% |
| Q4 2024 | $730.5M | +18% |
AMRX's revenue has grown year over year for 22 quarters in a row: $863M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +2.1 points |
| Q2 2026 | 16% | +0.9 points |
| Q1 2026 | 20% | +5.2 points |
| Q4 2025 | 14% | +3.4 points |
| Q3 2025 | 9% | -3.7 points |
| Q2 2025 | 15% | +1.8 points |
| Q1 2025 | 14% | +16 points |
| Q4 2024 | 10% | +8.1 points |
AMRX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AMRX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AMRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $66.5M | -37% |
| Q2 2026 | -$51.9M | -185% |
| Q1 2026 | -$34.9M | -$29.2M |
| Q4 2025 | $108.5M | +5.5% |
| Q3 2025 | $106.2M | -15% |
| Q2 2025 | $61M | +110% |
| Q1 2025 | -$5.8M | +$7.9M |
| Q4 2024 | $102.9M | -18% |
AMRX still generates free cash flow, though less than at its 2020 peak: $88M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AMRX on cash flow, with more consistent year-over-year improvement.
AMRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +7.6M shares |
| 1 year | +3.4% | +11M shares |
| 3 years | +117% | +181M shares |
| 5 years | +121% | +184M shares |
| Available history | +154% | +204M shares |
AMRX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AMRX Net Leverage
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AMRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.8 | Neutral |
| Stochastic | 86.7 | Overbought |
AMRX's weekly RSI is 69 (neutral) and its Stochastic is 87 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AMRX PE vs Healthcare Sector
| Metric | AMRX | Sector median | Relative |
|---|---|---|---|
| PE | 53x | 26x | 105% above |
| PE % | 40 | 29 | 11 pts above |
AMRX is trading at 53x earnings, a 105% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over AMRX on valuation relative to its sector.
AMRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.4 | 6.6% above |
| 20 week MA | $18.8 | 15% above |
| 50 week MA | $15.5 | 40% above |
| 100 week MA | $12.1 | 79% above |
| 200 week MA | $8.62 | 152% above |
AMRX is in an uptrend: it's above all five of its weekly moving averages, and 152% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
AMRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.51 | $4.43 | -1.8% |
| 2021 | $4.43 | $5.07 | +14% |
| 2022 | $5.07 | $2.20 | -57% |
| 2023 | $2.20 | $6.07 | +176% |
| 2024 | $6.07 | $7.82 | +29% |
| 2025 | $7.82 | $13.0 | +66% |
| 2026 YTD | $13.0 | $21.7 | +68% |
AMRX's yearly returns have swung widely, from +176% in 2023 to −57% in 2022. It's up 68% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AMRX on returns for 2026, with the stronger performance.